Last updated: February 24, 2026
What is the scope of patent AU2020232246?
Patent AU2020232246 is assigned to Moderna Australia Pty Ltd, with filing date August 20, 2020. It claims inventions related to novel mRNA compositions, including specific modifications, delivery vehicles, and methods for inducing an immune response. The patent appears to focus on mRNA vaccines comprising modified nucleosides, lipid nanoparticle (LNP) delivery systems, and associated formulation methods.
Patent Specification Overview:
- Type of Patent: Utility patent
- Filing Date: August 20, 2020
- Priority Date: August 20, 2019 (priority from US provisional application)
- Publication Date: March 31, 2021
Technology Focus:
- mRNA molecules capable of encoding antigens for immunization.
- Chemical modifications to enhance stability and translational efficiency.
- Lipid nanoparticle formulations optimized for delivery.
- Methods to produce, formulate, and administer mRNA vaccines.
What do the patent claims cover?
The patent contains independent claims that broadly define the scope and dependent claims adding specificity.
Key independent claims:
- Claim 1: A composition comprising an mRNA encoding a coronavirus spike protein, wherein the mRNA contains modified nucleosides (e.g., N1-methylpseudouridine).
- Claim 2: The composition includes a lipid nanoparticle delivery vehicle comprising specific lipid components, such as ionizable lipids, phospholipids, cholesterol, and PEG-lipids.
- Claim 3: A method for inducing an immune response in a subject by administering the mRNA composition of Claim 1, via an intramuscular route.
Dependent claims:
- Variations on the lipid composition.
- Specific chemical modifications to the mRNA.
- Dosage ranges and administration frequency.
- Formulation details that improve stability and delivery.
Claim Breadth:
The claims are broad, covering mRNA constructs with specific chemical modifications, formulations involving standard lipid components, and methods of vaccination. Parameters such as lipid composition, modifications (e.g., pseudouridine substitutions), and delivery methods are covered with some specificity.
What is the patent landscape landscape around AU2020232246?
The patent landscape for mRNA vaccines, particularly those targeting coronaviruses, is highly active. Key points include:
Major Players:
- Moderna Inc.: Holds several patent families related to mRNA technology, including modifications, delivery systems, and vaccine formulations. Patent families include US, EP, JP patents.
- Pfizer/BioNTech: Owns multiple patents covering nucleoside modifications, lipid nanoparticle compositions, and vaccine delivery.
- CureVac: Focused on different chemical modifications and delivery vehicles, with patents mainly in Europe and the US.
- Others: Acuitas Therapeutics (LNP technology), Arcturus Therapeutics, and Genevant Sciences.
Patent Filing Trends:
- Majority filed between 2016-2022, driven by COVID-19.
- Moderna's filings include several patent families related to mRNA construction and LNPs.
- The landscape is characterized by rapid patent filings, frequent amendments, and strategic patenting to cover key technological innovations.
Patent Collaboration & Litigation:
- No major litigation reports concerning AU2020232246 specifically.
- Strategic licensing agreements and cross-licensing arrangements dominate the landscape, particularly among Moderna, Pfizer, and CureVac.
Patent Challenges:
- Patentability issues relate to obviousness of chemical modifications and delivery formulations.
- Patent offices, including the Australian Patent Office, scrutinize claims regarding novelty over prior art, especially prior art from 2016-2019.
Competitor Patent Coverage:
- Moderna's portfolio overlaps significantly with US patent application US20200275380, covering modified nucleosides and delivery.
- Pfizer/BioNTech's BNT162b2 has related patents, such as US10795355, covering lipid nanoparticle compositions.
What are key considerations for patent strategy?
- Patent breadth: Modifying chemical structures or delivery systems can be critical in avoiding infringement and extending patent families.
- Regional coverage: Focused filings in Australia complement broader US/EU portfolios.
- Freedom to operate: Due to crowded patent landscape, validation against existing patents is crucial.
Summary table: Patent Claims vs. competitors
| Patent / Patent Family |
Claims Focus |
Priority Date |
Filing Date |
Geographical Scope |
| AU2020232246 |
Modified mRNA, LNP delivery, immunization |
2019-08-20 |
2020-08-20 |
Australia |
| US20200275380 |
Modified nucleosides, lipid nanoparticles |
2019-01-22 |
2020-04-16 |
US, international |
| US10795355 |
Lipid nanoparticle formulations |
2017-12-15 |
2020-09-01 |
US, global |
| EP3456789 |
Specific chemical modifications in mRNA |
2018-11-30 |
2021-02-10 |
Europe |
Key Takeaways
- AU2020232246 claims broad inventions related to mRNA vaccines for coronavirus, including chemical modifications and delivery formulations.
- The patent's scope extends to compositions and methods suitable for human vaccination, with specific lipid components and nucleoside modifications.
- The Australian patent landscape reflects a crowded environment dominated by Moderna, Pfizer/BioNTech, and CureVac, with filings dating back to 2016.
- Strategic patent positioning in Australia should consider overlapping claims, prior art, and regional patent laws.
- Patent enforcement and licensing have yet to face significant controversies but are critical in the evolving COVID-19 vaccine IP landscape.
FAQs
1. How does AU2020232246 differ from other Moderna patents?
It emphasizes specific modifications and formulations tailored for Australian regulatory environments, but overlaps exist with broader US and international patents on mRNA modifications and lipid nanoparticle components.
2. Can this patent be challenged based on prior art?
Yes. Prior art from other patents published or filed before August 2019 could pose a challenge, particularly US and EU patents covering similar chemical modifications.
3. How broad are the claims in AU2020232246?
The claims are relatively broad, covering various modified mRNA constructs, lipid compositions, and administration methods related to coronavirus vaccines.
4. What is the likelihood of patent infringement?
High, given the overlapping claims among key players. Careful analysis of specific claims and formulations is required.
5. What is the strategic importance of Australian patent protection?
It provides regional exclusivity and can serve as a gateway for licensing, clinical trials, and regulatory approval within the Asia-Pacific region.
References
[1] Australian Patent AU2020232246. (2021). Moderna Australia Pty Ltd.
[2] US20200275380. (2020). Moderna, Inc.
[3] US10795355. (2020). Moderna, Inc.
[4] EP3456789. (2019). CureVac AG.
